FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965843123> ?p ?o ?g. }

• W1965843123 abstract "Introduction Azathioprine (AZA) is an immunosuppressant of choice in inflammatory bowel disease (IBD). However, problems with lack of clinical response and toxicity have been encountered as the exact mode of action of AZA is not fully understood. It is thought that lymphocyte suppression may be involved. We aimed to determine if the lymphocyte count may be used to predict AZA efficacy in IBD. Methods We conducted a retrospective study of 75 men and women with IBD (42 Ulcerative Colitis (UC), 33 Crohn9s disease), maintained on AZA to investigate the relationship between the lymphocyte count and clinical course on AZA. Episodes of relapse on AZA were identified in these patients and the lymphocyte count at the visit immediately preceding the relapse recorded, as well as the relapse value itself. These were compared with values recorded during randomly selected visits with maintained remission. Other corresponding clinical data such as neutrophil, platelet, mean cell volume (MCV) counts and AZA dose were also noted. Results Mean lymphocyte count before AZA was 2.044 (95% CI 1.861 to 2.227)×109/l. This fell to 1.502 (1.445 to 1.559)×109/l while patients were on AZA (p=0.000). Lymphocyte counts in patients taking AZA varied significantly according to clinical course. At visits immediately prior to or at relapse, the lymphocyte count was 1.597 (1.454 to 1.741)×109/l and 1.631 (1.481 to 1.780)×109/l vs 1.433 (1.367 to 1.500)×109/l at visits with maintained remission (p=0.000). Of patients on AZA with a lymphocyte count below median values (1.5×109/l) 57.4% were in remission compared with 37.1% of patients with higher values. (p=0.000). Similar relationships between lymphocyte counts and clinical course were noted in both UC and Crohn9s disease separately. Other parameters also varied according to clinical course. MCV on treatment was significantly higher in patients in remission than prior to or at relapse (92.479 (91.662 to 93.296) fl vs 89.900 (88.145 to 91.655) fl and 89.992 (88.301 to 91.682) fl). In addition, on treatment neutrophil and platelet counts were significantly elevated prior to or at relapse. Significant differences in lymphocyte counts were also related to AZA dose. Doses >2 mg/kg were associated with lower lymphocyte counts (1.486 (1.339 to 1.633)×109/l) compared with 1.695 (1.618 to 1.772)×109/l on lower doses (p=0.039). Conclusion In patients with IBD, on AZA, a lower lymphocyte count is associated with a lower incidence of disease relapse and a higher likelihood of maintained remission. Variation in other parameters such as neutrophil, platelet and MCV counts may also predict clinical course on AZA. Studies on dosing according to lymphocyte count will be a useful step towards achieving better therapeutic response on AZA." @default.
• W1965843123 created "2016-06-24" @default.
• W1965843123 creator A5021675273 @default.
• W1965843123 creator A5088605520 @default.
• W1965843123 date "2010-05-01" @default.
• W1965843123 modified "2023-09-25" @default.
• W1965843123 title "W1269 Lower Lymphocyte Counts and Azathioprine Efficacy in Inflammatory Bowel Disease" @default.
• W1965843123 doi "https://doi.org/10.1016/s0016-5085(10)63160-5" @default.
• W1965843123 hasPublicationYear "2010" @default.
• W1965843123 type Work @default.
• W1965843123 sameAs 1965843123 @default.
• W1965843123 citedByCount "0" @default.
• W1965843123 crossrefType "journal-article" @default.
• W1965843123 hasAuthorship W1965843123A5021675273 @default.
• W1965843123 hasAuthorship W1965843123A5088605520 @default.
• W1965843123 hasConcept C126322002 @default.
• W1965843123 hasConcept C203014093 @default.
• W1965843123 hasConcept C2776760755 @default.
• W1965843123 hasConcept C2777761686 @default.
• W1965843123 hasConcept C2778260677 @default.
• W1965843123 hasConcept C2779134260 @default.
• W1965843123 hasConcept C2780479503 @default.
• W1965843123 hasConcept C71924100 @default.
• W1965843123 hasConcept C90924648 @default.
• W1965843123 hasConceptScore W1965843123C126322002 @default.
• W1965843123 hasConceptScore W1965843123C203014093 @default.
• W1965843123 hasConceptScore W1965843123C2776760755 @default.
• W1965843123 hasConceptScore W1965843123C2777761686 @default.
• W1965843123 hasConceptScore W1965843123C2778260677 @default.
• W1965843123 hasConceptScore W1965843123C2779134260 @default.
• W1965843123 hasConceptScore W1965843123C2780479503 @default.
• W1965843123 hasConceptScore W1965843123C71924100 @default.
• W1965843123 hasConceptScore W1965843123C90924648 @default.
• W1965843123 hasLocation W19658431231 @default.
• W1965843123 hasOpenAccess W1965843123 @default.
• W1965843123 hasPrimaryLocation W19658431231 @default.
• W1965843123 hasRelatedWork W1998745760 @default.
• W1965843123 hasRelatedWork W2003820520 @default.
• W1965843123 hasRelatedWork W2029535985 @default.
• W1965843123 hasRelatedWork W2110315816 @default.
• W1965843123 hasRelatedWork W2160632960 @default.
• W1965843123 hasRelatedWork W2324754113 @default.
• W1965843123 hasRelatedWork W2327216852 @default.
• W1965843123 hasRelatedWork W2359624430 @default.
• W1965843123 hasRelatedWork W2360753028 @default.
• W1965843123 hasRelatedWork W2371514434 @default.
• W1965843123 hasRelatedWork W2404008330 @default.
• W1965843123 hasRelatedWork W2434129841 @default.
• W1965843123 hasRelatedWork W2586216539 @default.
• W1965843123 hasRelatedWork W2808517732 @default.
• W1965843123 hasRelatedWork W2970986599 @default.
• W1965843123 hasRelatedWork W2980409798 @default.
• W1965843123 hasRelatedWork W3020278648 @default.
• W1965843123 hasRelatedWork W3025646292 @default.
• W1965843123 hasRelatedWork W3032368743 @default.
• W1965843123 hasRelatedWork W3092033766 @default.
• W1965843123 isParatext "false" @default.
• W1965843123 isRetracted "false" @default.
• W1965843123 magId "1965843123" @default.
• W1965843123 workType "article" @default.